The United States Patent and Trademark Office (USPTO) has confirmed the patentability of Rampart's key radiation protection claims following an Ex Parte Reexamination initiated by Egg Medical. The decision reinforces the strength of Rampart's intellectual property portfolio and underscores the company's continued commitment to advancing innovative, lead-free radiation protection solutions for clinicians and healthcare systems worldwide.

Rampart announces the launch of Lead-FreeERPD.com, a new educational resource center providing consensus summaries, ALARA education, clinical evidence, ERPD evaluation tools, and implementation resources to help healthcare organizations navigate the evolving standard of radiation safety.

Published jointly by six leading medical societies, a new expert consensus calls for the next evolution of ALARA and recognizes Enhanced Radiation Protection Devices (ERPDs) as a critical component of modern radiation safety. Rampart’s Lead-Free ERPD™ platform is helping hospitals implement these recommendations today through clinically validated, lead-free protection.

Healthcare teams in more than 35 states are now performing lead-apron-free procedures with Rampart’s Lead-Free ERPD™. Learn how Arizona’s new legislation marks another milestone in the growing movement toward safer, lead-free radiation protection.

Rampart is able to consistently deliver next-generation radiation protection to your lab within 30 days.

Mr. Williamson has over 25 years of medical device leadership experience, including helping scale Shockwave Medical to $500M+ in annual revenue.

Mr. Burbach brings decades of medical device leadership as the company advances its interventional radiation safety platform.

A coordinated series of clinical studies spanning multiple interventional specialties all evaluating the use of Rampart’s suite of Enhanced Radiation Protection Devices (ERPD).

Presentation Features First EVAR Case Performed with the Rampart Guardian—Achieving Radiation Exposure Lower Than a Cross-Country Flight